MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after the U.S. market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors must register online to participate, preferably a day in advance. A live and archived webcast will be available in the "Events" section of MaxCyte's investor relations website.
MaxCyte (NASDAQ: MXCT), azienda specializzata in piattaforme tecnologiche per l'ingegneria cellulare, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 6 agosto 2025, dopo la chiusura del mercato statunitense.
La società terrà una conference call alle 16:30 ora della costa orientale per discutere i risultati. Gli investitori devono registrarsi online per partecipare, preferibilmente con un giorno di anticipo. Una trasmissione in diretta e una registrazione saranno disponibili nella sezione "Eventi" del sito web delle relazioni con gli investitori di MaxCyte.
MaxCyte (NASDAQ: MXCT), una empresa de tecnología de plataformas para ingeniería celular, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025, tras el cierre del mercado estadounidense.
La compañía realizará una llamada conferencia a las 4:30 p.m., hora del Este para discutir los resultados. Los inversores deben registrarse en línea para participar, preferiblemente con un día de anticipación. Una transmisión en vivo y una grabación estarán disponibles en la sección "Eventos" del sitio web de relaciones con inversores de MaxCyte.
MaxCyte (NASDAQ: MXCT)는 세포 공학 플랫폼 기술 회사로서, 2025년 2분기 재무 실적 발표를 2025년 8월 6일 미국 시장 마감 후에 예정하고 있습니다.
회사는 결과를 논의하기 위해 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 참여를 위해 온라인으로 사전 등록해야 하며, 가급적 하루 전에 등록하는 것이 좋습니다. 생중계 및 녹화된 웹캐스트는 MaxCyte 투자자 관계 웹사이트의 "이벤트" 섹션에서 제공됩니다.
MaxCyte (NASDAQ : MXCT), une entreprise spécialisée dans les technologies de plateformes d'ingénierie cellulaire, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 6 août 2025, après la clôture du marché américain.
L'entreprise tiendra une conférence téléphonique à 16h30, heure de l'Est pour discuter des résultats. Les investisseurs doivent s'inscrire en ligne pour participer, de préférence un jour à l'avance. Une diffusion en direct ainsi qu'une rediffusion seront disponibles dans la section « Événements » du site web des relations investisseurs de MaxCyte.
MaxCyte (NASDAQ: MXCT), ein Unternehmen für zelluläre Engineering-Plattformtechnologie, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 6. August 2025 nach Börsenschluss in den USA geplant.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren müssen sich online registrieren, um teilzunehmen, vorzugsweise einen Tag im Voraus. Ein Live- und ein archivierter Webcast werden im Bereich "Veranstaltungen" auf der Investor-Relations-Website von MaxCyte verfügbar sein.
- None.
- None.
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
When will MaxCyte (MXCT) release Q2 2025 earnings?
What time is MaxCyte's Q2 2025 earnings conference call?
How can investors join MaxCyte's Q2 2025 earnings call?
Where can I find MaxCyte's Q2 2025 earnings webcast?
